Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 50
Filtrar
1.
Acta Gastroenterol Belg ; 85(1): 7-14, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35304988

RESUMO

Background and study aims: This study evaluated the longterm outcomes of mainly endoscopic hemostatic therapy for gastrointestinal variceal bleeding and of the transition of hemostatic therapy. Patients and methods: Among 1,163 patients treated for gastrointestinal varices between April 2006 and June 2020, a total of 125 patients who underwent emergency hemostatic therapy were enrolled. Survival rates and secondary evaluation points were analyzed. Additionally, patients were classified into two groups: the previous and latter term. Patients' background, therapeutic method, and treatment results were compared between the groups. Results: 94.4% had cirrhosis. The average Child-Pugh score was 8.90. Successful primary hemostasis rate was 98.4%, and 5.6% died within 2 weeks, all with a Child-Pugh score ≥9. The respective 1- and 5-year survival rates for Child-Pugh grade A/B were 81.3% and 55.4%, while those for Child-Pugh grade C were 58.1% and 17.8%. Child-Pugh grade C or hepatocellular carcinoma was significantly associated with poor prognosis. In total, 21.6% experienced variceal re-bleeding; 62.9% of these cases were triggered by continued alcohol consumption. There was no significant difference in survival between patients with and without variceal re-bleeding and in post-treatment survival between the previous and latter terms. In the latter term, the number of cases caused by continued alcohol consumption significantly increased. Conclusions: Multidisciplinary treatment and continuation of proper management after hemostatic therapy for variceal bleeding are crucial. Continued alcohol consumption leads to variceal bleeding and re-bleeding; its proper management, including alcohol abstinence, is one of the major challenges left in the post-directacting antivirals era.


Assuntos
Varizes Esofágicas e Gástricas , Hemostáticos , Hepatite C Crônica , Neoplasias Hepáticas , Varizes , Antivirais , Varizes Esofágicas e Gástricas/complicações , Varizes Esofágicas e Gástricas/terapia , Hemorragia Gastrointestinal/tratamento farmacológico , Hemorragia Gastrointestinal/etiologia , Hemostasia , Hemostáticos/uso terapêutico , Hepatite C Crônica/complicações , Humanos
2.
Dis Esophagus ; 21(4): 355-63, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18477259

RESUMO

The Los Angeles classification system is the most widely employed criteria associated with the greatest interobserver agreement among endoscopists. In Japan, the Los Angeles classification system has been modified (modified LA system) to include minimal changes as a distinct grade of reflux esophagitis, rather than as auxiliary findings. This adds a further grading M defined as minimal changes to the mucosa, such as erythema and/or whitish turbidity. The modified LA system has come to be used widely in Japan. However, there have been few reports to date that have evaluated the interobserver agreement in diagnosis when using the modified LA classification system incorporating these minimal changes as an additional grade. A total of 100 endoscopists from university hospitals and community hospitals, as well as private practices in the Osaka-Kobe area participated in the study. A total of 30 video clips of 30-40 seconds duration, mostly showing the esophagocardiac junction, were created and shown to 100 endoscopists using a video projector. The participating endoscopists completed a questionnaire regarding their clinical experience and rated the reflux esophagitis as shown in the video clips using the modified LA classification system. Agreement was assessed employing kappa (kappa) statistics for multiple raters. The kappa-value for all 91 endoscopists was 0.094, with a standard error of 0.002, indicating poor interobserver agreement. The endoscopists showed the best agreement on diagnosing grade A esophagitis (0.167), and the poorest agreement when diagnosing grade M esophagitis (0.033). The kappa-values for the diagnoses of grades N, M, and A esophagitis on identical video pairs were 0.275-0.315, with a standard error of 0.083-0.091, indicating fair intraobserver reproducibility among the endoscopists. The study results consistently indicate poor agreement regarding diagnoses as well as fair reproducibility of these diagnoses by endoscopists using the modified LA classification system, regardless of age, type of practice, past endoscopic experience, or current workload. However, grade M reflux esophagitis may not necessarily be irrelevant, as it may suggest an early form of reflux disease or an entirely new form of reflux esophagitis. Further research is required to elucidate the pathophysiological basis of minimal change esophagitis.


Assuntos
Esofagite Péptica/classificação , Esofagite Péptica/diagnóstico , Esofagoscopia , Variações Dependentes do Observador , Adulto , Idoso , Esofagite Péptica/patologia , Feminino , Humanos , Japão , Masculino , Pessoa de Meia-Idade
3.
Br J Pharmacol ; 149(7): 888-97, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17043674

RESUMO

BACKGROUND AND PURPOSE: Although inorganic arsenite (As(III)) is toxic in humans, it has recently emerged as an effective chemotherapeutic agent for acute promyelocytic leukemia (APL). In humans and most animals, As(III) is enzymatically methylated in the liver to weakly toxic dimethylarsinic acid (DMAs(V)) that is a major pentavalent methylarsenic metabolite. Recent reports have indicated that trivalent methylarsenicals are produced through methylation of As(III) and participate in arsenic poisoning. Trivalent methylarsenicals may be generated as arsenical-glutathione conjugates, such as dimethylarsinous glutathione (DMAs(III)G), during the methylation process. However, less information is available on the cytotoxicity of DMAs(III)G. EXPERIMENTAL APPROACH: We synthesized and purified DMAs(III)G using high performance TLC (HPTLC) methods and measured its cytotoxicity in rat liver cell line (TRL 1215 cells). KEY RESULTS: DMAs(III)G was highly cytotoxic in TRL 1215 cells with a LC(50) of 160 nM. We also found that DMAs(III)G molecule itself was not transported efficiently into the cells and was not cytotoxic; however it readily became strongly cytotoxic by dissociating into trivalent dimethylarsenicals and glutathione (GSH). The addition of GSH in micromolar physiological concentrations prevented the breakdown of DMAs(III)G, and the DMAs(III)G-induced cytotoxicity. Physiological concentrations of normal human serum (HS), human serum albumin (HSA), and human red blood cells (HRBC) also reduced both the cytotoxicity and cellular arsenic uptake induced by exposure to DMAs(III)G. CONCLUSIONS AND IMPLICATIONS: These findings suggest that the significant cytotoxicity induced by DMAs(III)G may not be seen in healthy humans, even if DMAs(III)G is formed in the body from As(III).


Assuntos
Ácido Cacodílico/análogos & derivados , Glutationa/análogos & derivados , Glutationa/farmacologia , Hepatócitos/efeitos dos fármacos , Animais , Antineoplásicos/efeitos adversos , Antineoplásicos/metabolismo , Intoxicação por Arsênico/metabolismo , Arsenicais/síntese química , Arsenicais/metabolismo , Arsenitos/efeitos adversos , Arsenitos/metabolismo , Ácido Cacodílico/química , Ácido Cacodílico/metabolismo , Ácido Cacodílico/toxicidade , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Cromatografia em Camada Fina/métodos , Relação Dose-Resposta a Droga , Eritrócitos , Glutationa/síntese química , Glutationa/química , Glutationa/metabolismo , Glutationa/toxicidade , Hepatócitos/metabolismo , Humanos , Concentração Inibidora 50 , Metilação , Ratos , Ratos Endogâmicos F344 , Albumina Sérica/metabolismo , Fatores de Tempo
4.
Toxicol Lett ; 148(1-2): 133-9, 2004 Mar 14.
Artigo em Inglês | MEDLINE | ID: mdl-15019097

RESUMO

Metallothionein (MT) is a small sulfhydryl-rich protein whose levels are elevated by various inducers of organelle stresses, such as nuclear stress (cisplatin), mitochondrial stress (antimycin A, 2,4-dinitrophenol) and lysosomal stress (paraquat). Although abnormal folding of protein in the endoplasmic reticulum (ER) causes ER stress, induction of MT synthesis by ER stress has never been investigated. In this study, we examined the induction of MT by an inducer of ER stress, tunicamycin (Tun), which induces ER stress by inhibiting N-linked glycosylation of protein in the ER. Administration of Tun (0.5-1.5 mg/kg, sc) increased hepatic MT levels in C57BL/6J mice (3.1-fold). The maximal increase in hepatic MT was observed 48-96 h after the administration of Tun (1.0 mg/kg). Expressions of MT-I, II and glucose-regulated protein 78 (Bip/GRP78), which is a molecular chaperone induced by ER stress, mRNA were also detected by administration of Tun. Thapsigargin (Thap), a generator of ER stress by inhibiting ER Ca(2+)-ATPase, also increased both hepatic MT levels and expression of MT-I and -II mRNA. The level of expression of Bip/GRP78 mRNA induced by Tun administration in MT-null mice was greater than that in wild-type mice. Taken together, these findings suggest that inhibitors of ER are potent inducers of MT.


Assuntos
Antibacterianos/toxicidade , Retículo Endoplasmático/patologia , Retículo Endoplasmático/fisiologia , Metalotioneína/biossíntese , Tunicamicina/toxicidade , Animais , ATPases Transportadoras de Cálcio/farmacologia , Chaperona BiP do Retículo Endoplasmático , Genótipo , Glicosilação , Fígado/química , Masculino , Metalotioneína/farmacologia , Camundongos , Camundongos Endogâmicos C57BL , RNA Mensageiro/biossíntese
5.
Int J Mol Med ; 8(4): 359-63, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11562772

RESUMO

p53 is one of the most important tumor suppressor genes. Mutation of the p53 gene can be detected immunohistochemically as over-expression of its protein in the nucleus. The p53 gene product is known to regulate cell growth and proliferation. Genetic alterations related to the carcinogenesis or progression of esophageal cancer are poorly understood. We examined accumulation of p53 protein in esophageal squamous cell carcinomas including early-stage cancers, and its clinicopathological significance. p53 immunoreactivity in the cancer tissues was found in 61 (79.2%) of 77 esophageal squamous cell carcinomas. Over-expression of p53 protein (diffusely and focally positive staining) was seen in 70.1% (54/77). p53 over-expression was detected not only in the cases of in situ or intramucosal carcinomas, but also in invasive carcinomas. No significant correlations were found between p53 over-expression and clinicopathological features such as depth of tumor invasion, lymph node metastasis or venous/lymphatic invasion. These results suggested that p53 mutations may be closely associated with the early-stage of pre-invasive esophageal carcinoma, and p53 gene mutations may play an important role in the carcinogenesis of human esophageal cancer.


Assuntos
Carcinoma de Células Escamosas/patologia , Neoplasias Esofágicas/patologia , Proteína Supressora de Tumor p53/metabolismo , Idoso , Carcinoma de Células Escamosas/metabolismo , Neoplasias Esofágicas/metabolismo , Feminino , Humanos , Imuno-Histoquímica , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica
6.
Oncol Rep ; 8(5): 1079-83, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11496320

RESUMO

Case 1: a patient was diagnosed as having ascending colon cancer with right ovarian metastasis, and underwent palliative right hemicolectomy plus oophorectomy. The tumor was a well-differentiated adenocarcinoma with right ovarian metastasis, and the disease was classified as stage IV. Oral chemotherapy with UFT plus LV was performed for about 3 years, and the patient is still being followed up with no recurrence at 5 years postoperatively. Case 2: a patient was diagnosed as having incomplete large bowel obstruction caused by ascending colon cancer, and underwent curative right hemicolectomy. The tumor was a moderately differentiated adenocarcinoma, and the disease was classified as stage II. Since multiple liver metastases developed at 3 months postoperatively, oral chemotherapy with UFT plus LV was started. Imaging studies showed the complete elimination of liver metastases after 2 months. Subsequently, liver metastasis recurred about 10 months later. The patient died of unrelated cerebral infarction at 2 years and 6 months postoperatively.


Assuntos
Adenocarcinoma/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Leucovorina/uso terapêutico , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Ovarianas/tratamento farmacológico , Tegafur/uso terapêutico , Uracila/uso terapêutico , Adenocarcinoma/secundário , Adenocarcinoma/cirurgia , Administração Oral , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Colectomia , Neoplasias do Colo/patologia , Neoplasias do Colo/cirurgia , Feminino , Humanos , Leucovorina/administração & dosagem , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/cirurgia , Estadiamento de Neoplasias , Neoplasias Ovarianas/secundário , Neoplasias Ovarianas/cirurgia , Ovariectomia , Período Pós-Operatório , Indução de Remissão , Tegafur/administração & dosagem , Tomografia Computadorizada por Raios X , Uracila/administração & dosagem
7.
Mol Cell Biochem ; 219(1-2): 51-6, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11354253

RESUMO

A study of the involvement of glutathione (GSH) in cellular resistance to cisplatin was performed using methylmercury-resistant sublines (PC12/TM series) of the PC12 line of rat pheochromocytoma cells. The seven clonal sublines of PC12 cells (PC12/TM, PC12/TM2, PC12/TM5, PC12/TM11, PC12/TM15, PC12/TM23, PC12/TM26) used in the study had intracellular levels of GSH that ranged from 8.7-39.9 nmol/mg protein. The intracellular level of GSH was significantly correlated (p < 0.01, r = 0.87) with the sensitivity to cisplatin of PC12 cells and the seven sublines. Among the seven sublines, PC12/TM cells contained the highest concentration of GSH and were the most resistant to cisplatin. Treatment of PC12/TM cells with L-buthionine-SR-sulfoximine, which reduced the level of GSH to that in the parental PC12 cells, significantly reduced the resistance of the cells to cisplatin. The amount of platinum accumulated by resistant PC12/TM cells after treatment with cisplatin was higher than that by sensitive PC12 cells. These results suggest that the intracellular level of GSH might be directly involved in the resistance to cisplatin of these cell lines. However, a high intracellular concentration of GSH does not appear to contribute to a decrease in the accumulation of cisplatin in these cells.


Assuntos
Butionina Sulfoximina/farmacologia , Cisplatino/toxicidade , Glutationa/metabolismo , Platina/farmacocinética , Animais , Cisplatino/farmacocinética , Células Clonais , Relação Dose-Resposta a Droga , Resistência a Medicamentos , Inibidores Enzimáticos/farmacologia , Glutationa/análise , Células PC12 , Ratos , Sensibilidade e Especificidade , Estatística como Assunto , Fatores de Tempo
8.
Endoscopy ; 33(3): 253-6, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11293759

RESUMO

BACKGROUND AND STUDY AIMS: Colorectal endoscopic mucosal resection (EMR) has limitations both anatomically and technically when it is done using the conventional snare wire method. The aim of this study was to develop a new method and instrument for colorectal EMR. METHODS: A total of 21 EMR procedures were done using ten surgical specimens. Saline was injected into the normal submucosa of freshly resected colorectal specimens to prepare a pseudotumor. EMR was performed experimentally by employing a three-channel outer tube with three forceps and a colonoscope with a needle-type precutting knife. This method was assessed in terms of safety and the size of the resected specimens. RESULTS: Perforation occurred only twice in the initial stage of this study. The size of the specimens resected by EMR was 28-39 mm (long diameter 34.8+/-3.11), by 22-28 mm (short diameter 25.8+/-2.07). CONCLUSION: This method can achieve safety and en bloc mucosal resection to the submucosal layer. This novel approach may be promising for clinical application as a new form of endoscopic surgery.


Assuntos
Colonoscópios , Colonoscopia/métodos , Neoplasias Colorretais/cirurgia , Mucosa Intestinal/cirurgia , Instrumentos Cirúrgicos , Humanos , Técnicas In Vitro
9.
Oncol Rep ; 8(1): 111-4, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11115580

RESUMO

A patient who had undergone radical gastrectomy for synchronous gastric cancer (T(1)N(0)M(0), stage I) and duodenal cancer (Tis, stage 0) in November 1987 was found to have esophageal cancer in November 1994, and underwent radical thoracolaparotomy at our hospital (T(1)N(0)M(0), stage I). After follow-up for about 3.5 years, renal cancer was detected in April 1998, and radical nephrectomy was performed (T(1)N(0)M(0), stage I). Two years later, in April 2000, the patient was found to have a polypoid lesion in the colonic conduit used for reconstruction after esophagectomy, and endoscopic mucosal resection was performed (Tis, stage 0). The patient remains under careful follow-up, including observation of the colonic conduit and the residual large intestine.


Assuntos
Adenocarcinoma de Células Claras/patologia , Adenocarcinoma/patologia , Carcinoma de Células Renais/patologia , Carcinoma de Células Escamosas/patologia , Neoplasias Esofágicas/patologia , Neoplasias Gastrointestinais/patologia , Neoplasias Renais/patologia , Neoplasias Primárias Múltiplas/patologia , Segunda Neoplasia Primária/patologia , Adenocarcinoma/cirurgia , Adenocarcinoma de Células Claras/cirurgia , Carcinoma de Células Renais/cirurgia , Carcinoma de Células Escamosas/cirurgia , Neoplasias do Colo/patologia , Neoplasias do Colo/cirurgia , Neoplasias Duodenais/patologia , Neoplasias Duodenais/cirurgia , Neoplasias Esofágicas/cirurgia , Seguimentos , Gastrectomia , Neoplasias Gastrointestinais/cirurgia , Humanos , Neoplasias Renais/cirurgia , Masculino , Pessoa de Meia-Idade , Neoplasias Primárias Múltiplas/cirurgia , Segunda Neoplasia Primária/cirurgia , Nefrectomia , Período Pós-Operatório , Neoplasias Gástricas/patologia , Neoplasias Gástricas/cirurgia
11.
Toxicol Appl Pharmacol ; 169(2): 177-84, 2000 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-11097870

RESUMO

Tributyltin (TBT) and triphenyltin (TPT) are known to cause imposex, the superimposing of male genitals on female ones, in some species of gastropods. However, the molecular mechanism of the trialkyltin-induced endocrine dysfunction remains to be elucidated. To clarify the effects of organotin compounds on the activation of androgen receptor (AR)-mediated responses in mammals, a LA16 clone that stably expresses androgen-responsive luciferase reporter gene and proliferates in response to androgen was established from human prostate cancer cell line LNCaP. Stimulation of LA16 cells with 100 nM TBT or 1 nM TPT enhanced both AR-dependent transcription of luciferase gene and cell growth to the same extent as those by 1 nM dihydrotestosterone (DHT). TBT or TPT also enhanced the DNA synthesis and expression of endogenous AR target genes such as prostate specific antigen, but not the expression of AR itself. However, an androgen antagonist, flutamide, did not inhibit the TBT- or TPT-induced AR activation. On the other hand, simultaneous treatment of LA16 cells with DHT and TBT or TPT caused highly enhanced effects on AR activation. These results indicate that trialkyltin compounds have an ability to activate AR-mediated transcription in mammalian cells and suggest that a novel target site other than the ligand-binding site of AR is involved in this activation.


Assuntos
Androgênios/farmacologia , Compostos Orgânicos de Estanho/farmacologia , Neoplasias da Próstata/patologia , Transcrição Gênica/efeitos dos fármacos , Compostos de Trialquitina/farmacologia , Antagonistas de Androgênios/farmacologia , Northern Blotting , Divisão Celular/efeitos dos fármacos , DNA de Neoplasias/biossíntese , Flutamida/farmacologia , Humanos , Luciferases/metabolismo , Masculino , Compostos Orgânicos de Estanho/química , Compostos Orgânicos de Estanho/metabolismo , Plasmídeos/genética , Timidina/metabolismo , Transfecção , Compostos de Trialquitina/química , Compostos de Trialquitina/metabolismo , Células Tumorais Cultivadas
12.
Cancer Lett ; 159(1): 73-8, 2000 Oct 16.
Artigo em Inglês | MEDLINE | ID: mdl-10974408

RESUMO

beta-Catenin has been identified as an oncogene in several tumors including colorectal cancers. beta-Catenin gene is activated by interstitial deletions involving exon 3 in colorectal carcinomas of Japanese population, in contrast to amino acid substitutions detected among Caucasian population. The aim of this study was to examine the type and frequency of beta-catenin gene mutation during early stages of colorectal tumorigenesis. We screened 100 colorectal adenomas for somatic mutations in the beta-catenin gene by single-strand conformation polymorphism method, as well as polymerase chain reaction amplification. In cases with mutations, sequencing analyses and immunohistochemical staining were also performed. Somatic interstitial deletions of 272-413 bp, each of which included all parts of exon 3, were detected in three tumors. However, no adenoma carried missense mutations. We confirmed accumulation of aberrant beta-catenin protein in cytoplasm and nuclei of adenoma cells by immunohistochemical analysis. Our results suggested that activation of the beta-catenin gene by interstitial deletions involving exon 3 might be less frequent compared with frequent alterations of adenomatous polyposis coli (APC) gene, but could be an early event in colorectal tumorigenesis equivalent to APC gene alterations in the Japanese population.


Assuntos
Adenoma/genética , Neoplasias Colorretais/genética , Proteínas do Citoesqueleto/genética , Éxons/genética , Transativadores , Adenoma/metabolismo , Adenoma/patologia , Sequência de Bases , Neoplasias Colorretais/metabolismo , Neoplasias Colorretais/patologia , Proteínas do Citoesqueleto/análise , Análise Mutacional de DNA , DNA de Neoplasias/química , DNA de Neoplasias/genética , Regulação da Expressão Gênica , Humanos , Imuno-Histoquímica , Mutação , Reação em Cadeia da Polimerase , Polimorfismo Conformacional de Fita Simples , Deleção de Sequência , beta Catenina
13.
Int J Oncol ; 17(4): 701-5, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10995880

RESUMO

Sialyl Le(a) antigen (CA19-9), a member of a family of high molecular weight glycoproteins, was originally described as a gastrointestinal- and pancreatic-specific tumor marker. Recent studies have demonstrated that sialyl Le(a) is a ligand for E-selectin and may play an important role in tumor metastasis. However, expression patterns of sialyl Le(a) have not yet been established in human esophageal carcinomas. In this study, we examined sialyl Le(a) expression and its histopathological localization in human esophageal squamous cell carcinoma. Sialyl Le(a) immunoreactivity was detected in 28 (51.9%) of the 54 esophageal squamous cell carcinomas, regardless of the depth of tumor invasion, vascular invasion or lymph nodal status. In 13 cases (29.5%), significant sialyl Le(a) expression was detected not only in the intramucosal carcinoma components, but also in the invasive carcinoma components. These observation suggested that sialyl Le(a) expression is associated with early-stage cancer progression.


Assuntos
Carcinoma de Células Escamosas/patologia , Neoplasias Esofágicas/patologia , Gangliosídeos/biossíntese , Antígeno CA-19-9 , Carcinoma de Células Escamosas/metabolismo , Neoplasias Esofágicas/metabolismo , Humanos , Imuno-Histoquímica
14.
Jpn J Cancer Res ; 91(1): 91-8, 2000 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-10744049

RESUMO

Plasmid pSV2MT-I encoding mouse metallothionein-I (MT-I) designed to be expressed under the control of an SV40 promoter was introduced into human HeLa S3 cells. Several transformants (HeLa/MTH) carrying multi-copies of mouse MT-I cDNA in their genomes were isolated. These transformants produced 4 to 20-fold larger amounts of MT than their parent cells. The MT levels in HeLa/MTH were well correlated with the extent of resistance to cadmium, but not with that to cis-platinum (cis-DDP) in vitro. To study the role of MT in resistance to cis-DDP in vivo, nude mice were inoculated subcutaneously with two independent HeLa/MTH clones. MT levels in these tumors were about 3-fold higher than those in the parental cells. The growth of tumors derived from either HeLa/MTH clone was not inhibited in the presence of 15 micromol/kg of cis-DDP, which completely inhibited the growth of tumors derived from the parental HeLa cells. These data strongly suggest that the elevated level of MT confers resistance to cis-DDP in vivo but not in vitro. Thus, the results of this study indicate that in vitro determinations of the influence of MT on cis-DDP resistance may underestimate its importance in in vivo situations.


Assuntos
Antineoplásicos/farmacologia , Cisplatino/farmacologia , Resistencia a Medicamentos Antineoplásicos , Metalotioneína/biossíntese , Animais , Antioxidantes/metabolismo , Northern Blotting , Southern Blotting , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Feminino , Glutationa/metabolismo , Células HeLa , Humanos , Camundongos , Camundongos Nus , Plasmídeos , Fatores de Tempo , Transfecção
15.
J Pharmacol Exp Ther ; 292(3): 1080-6, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10688626

RESUMO

Cadmium is a hazardous heavy metal existing ubiquitously in the environment, but the mechanism of cadmium transport into mammalian cells has been poorly understood. Recently, we have established a cadmium-resistant cell line (Cd-rB5) from immortalized metallothionein-null mouse cells, and found that Cd-rB5 cells exhibited a marked decrease in cadmium uptake. To investigate the mechanism of altered uptake of cadmium in Cd-rB5 cells, incorporation of various metals was determined simultaneously using a multitracer technique. Cd-rB5 cells exhibited a marked decrease in manganese incorporation as well as that of cadmium. However, the reduced uptake of manganese was observed only at low concentrations, suggesting that a high-affinity component of the Mn(2+) transport system was suppressed in Cd-rB5 cells. Competition experiments and kinetic analyses revealed that low concentrations of Cd(2+) and Mn(2+) share the same high-affinity pathway for their entry into cells. The mutual competition of Cd(2+) and Mn(2+) uptake was also observed in HeLa, PC12, and Caco-2 cells. The highest uptake of Cd(2+) and Mn(2+) by parental cells occurred at neutral pH, suggesting that this pathway is different from a divalent metal transporter 1 that can transport various divalent metals including Cd(2+) and Mn(2+) under acidic conditions. These results suggest that a high-affinity Mn(2+) transport system is used for mammalian cellular cadmium uptake, and that the suppression of this pathway caused a marked decrease in cadmium accumulation in cadmium-resistant metallothionein-null cells.


Assuntos
Cádmio/metabolismo , Manganês/metabolismo , Metalotioneína/fisiologia , Animais , Transporte Biológico , Linhagem Celular , Resistência a Medicamentos , Concentração de Íons de Hidrogênio , Camundongos
16.
Biochem Pharmacol ; 59(4): 401-5, 2000 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-10644048

RESUMO

Because the up-regulation of telomerase in most cancer tissues is considered to be responsible for the unlimited proliferation of cancer cells, suppression of telomerase activity is an attractive potential target for cancer therapy. The mechanism for the activation of telomerase in cancer cells, however, is still unclear. In the present study, we demonstrated that Zn induces an enhancement of telomerase activity in the human renal cell carcinoma (NRC-12) and prostatic cancer (DU145) cell lines. The maximum elevation of the activity was observed 6 hr after treatment with 100 microM Zn; it was diminished by the addition of either metal chelator or cycloheximide. Other metals such as Cd and Cu also enhanced telomerase activity but to a lesser extent, and no correlation between the activation of telomerase and the induction of metallothionein was observed. Our findings provide the first evidence that metals, especially Zn, can modulate telomerase activity in cancer cells.


Assuntos
Telomerase/metabolismo , Zinco/farmacologia , Cádmio/metabolismo , Cádmio/farmacologia , Cobre/metabolismo , Cobre/farmacologia , Ativação Enzimática , Humanos , Neoplasias Renais , Masculino , Neoplasias da Próstata , Células Tumorais Cultivadas , Zinco/metabolismo
17.
Prostate ; 43(2): 144-9, 2000 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-10754530

RESUMO

BACKGROUND: Most prostate cancer cells respond to initial hormonal therapy; however, some of them eventually acquire resistance to the hormonal therapy. Hormone-independent prostate cancer usually exhibits resistance to chemotherapy and radiotherapy. Antioxidant systems are known to be involved in the resistance of cancer cells to chemotherapy and radiotherapy. Therefore, it is of significance to examine antioxidant systems of hormone-independent prostate cancer for enhancing the efficacy of cancer therapy. METHODS: Three cell lines of human hormone-independent prostate cancer (PC-3, PC-3 MA2, and HPC36M) were examined for activities of superoxide dismutase, catalase, and glutathione peroxidase, and for levels of protein and nonprotein thiols such as metallothionein, glutathione, and thioredoxin. Sensitivity of these cells to anticancer drugs and inducers of reactive oxygen species such as paraquat, tert-butylhydroperoxide, and hydrogen peroxide was determined by microtiter assay. RESULTS: PC-3 and PC-3 MA2, which were derived from bone metastases, were resistant to paraquat, hydrogen peroxide, and cisplatin compared with HPC36M, which was obtained from the primary prostate cancer. However, HPC36M was resistant to vinblastine compared with PC-3 and PC-3 MA2. Both PC-3 and PC-3 MA2 had higher activities of catalase and glutathione peroxidase and higher levels of glutathione and metallothionein than HPC36M. CONCLUSIONS: These data suggest that enhanced ability in scavenging free radicals by antioxidant enzymes and thiol compounds may, at least in part, contribute to the resistance of bone metastatic prostate cancer during chemotherapy.


Assuntos
Androgênios/fisiologia , Oxirredutases/metabolismo , Neoplasias da Próstata/fisiopatologia , Antineoplásicos/farmacologia , Humanos , Masculino , Neoplasias da Próstata/metabolismo , Neoplasias da Próstata/patologia , Espécies Reativas de Oxigênio/metabolismo , Compostos de Sulfidrila/metabolismo , Células Tumorais Cultivadas/efeitos dos fármacos
18.
Toxicol Appl Pharmacol ; 160(3): 279-88, 1999 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-10544062

RESUMO

Methylmercury (MeHg) is known to interfere with cell cycle progression by disruption of microtubules. The relationship between the changes in cell cycle and the induction of apoptosis caused by MeHg was investigated in cultured mammalian cells. MeHg caused nuclear fragmentation and DNA ladder formation in rat pheochromocytoma (PC12) and mouse neuroblastoma cells exposed to MeHg. Flow cytometric analysis revealed that the occurrence of apoptosis was preceded by the accumulation of cells in G2/M after MeHg treatment. Exposure to colchicine, a well-characterized mitotic inhibitor, also caused G2/M-phase arrest followed by the appearance of apoptotic cells. These results suggest that G2/M-phase arrest through the disruption of microtubules is an important event in the development of apoptosis by MeHg. MeHg treatment led to G2/M-phase arrest followed by apoptosis in nonneuronal HeLa cells also. Bcl-2 was phosphorylated by MeHg treatment in HeLa cells but not in PC12 cells; however, p53 expression was not changed in either cell line. Thus, MeHg induces apoptosis via a p53-independent pathway in both cell lines, however, different pathways may be activated after the disruption of microtubules in PC12 and HeLa cells.


Assuntos
Apoptose/efeitos dos fármacos , Compostos de Metilmercúrio/toxicidade , Microtúbulos/efeitos dos fármacos , Neurônios/citologia , Neurônios/efeitos dos fármacos , Animais , Apoptose/fisiologia , Ciclo Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Separação Celular , Colchicina/farmacologia , Fragmentação do DNA/efeitos dos fármacos , DNA de Neoplasias/análise , Relação Dose-Resposta a Droga , Citometria de Fluxo , Células HeLa/efeitos dos fármacos , Humanos , Camundongos , Neuroblastoma , Células PC12/efeitos dos fármacos , Fosforilação , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Ratos , Fatores de Tempo , Proteína Supressora de Tumor p53/metabolismo
19.
Life Sci ; 65(14): PL177-82, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10530804

RESUMO

Metallothionein (MT) is known to play a predominant role in the protection of cells from cadmium (Cd) toxicity. To investigate other factors involved in Cd resistance, we established Cd-resistant cell lines from simian virus 40-transformed MT null fibroblasts. Cd-resistant MT null cells, Cd-rA7 and Cd-rB5, developed approximately 10-fold resistance to Cd compared to parental cells, but showed no cross-resistance to Zn, Cu, Hg, Ni, As, cisplatin or H2O2. Accumulation of Cd in the resistant cells was 13-18% of that of parental cells after treatment with Cd for 24 h. A short-term experiment revealed that the rate of Cd incorporation into the Cd-resistant cells was suppressed, and the rate of Cd release was enhanced in the resistant cells compared with that of parental cells. These results indicate that the altered transport of Cd, slow uptake and rapid release, may confer resistance to Cd on the Cd-resistant cells established from MT null fibroblasts.


Assuntos
Intoxicação por Cádmio/prevenção & controle , Cádmio/metabolismo , Metalotioneína/análise , Animais , Intoxicação por Cádmio/metabolismo , Linhagem Celular Transformada , Sobrevivência Celular/efeitos dos fármacos , Citoproteção , Resistência a Medicamentos , Fibroblastos/metabolismo , Camundongos
20.
Carcinogenesis ; 20(8): 1625-7, 1999 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10426817

RESUMO

We examined the carcinogenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in transgenic mice deficient in the metallothionein (MT) I and II genes and in control (129/Sv) mice. Both strains of mice were given BBN for 8 weeks with or without Zn treatment. All mice were killed at 12 weeks after the cessation of BBN administration. BBN induced bladder tumors in 75% of MT null mice and in 43% of 129/Sv mice. The average number of bladder tumors per mouse was significantly higher in MT null mice (1. 18 +/- 0.27) than in 129/Sv mice (0.43 +/- 0.20). Zn treatment suppressed the carcinogenicity of BBN in 129/Sv mice but not in MT null mice. Histopathological examination of the tumors revealed that the malignant potential of bladder tumors in 129/Sv mice was greater than that in MT null mice. These results indicate that MT is an important modulator of carcinogenicity of BBN in the bladder of mice.


Assuntos
Butilidroxibutilnitrosamina/toxicidade , Carcinógenos/toxicidade , Cloretos/farmacologia , Metalotioneína/efeitos dos fármacos , Neoplasias da Bexiga Urinária/induzido quimicamente , Compostos de Zinco/farmacologia , Animais , Butilidroxibutilnitrosamina/farmacologia , Testes de Carcinogenicidade , Carcinógenos/antagonistas & inibidores , Carcinoma de Células de Transição/induzido quimicamente , Carcinoma de Células de Transição/metabolismo , Metalotioneína/deficiência , Metalotioneína/fisiologia , Camundongos , Camundongos Transgênicos , Neoplasias da Bexiga Urinária/metabolismo , Neoplasias da Bexiga Urinária/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA